olfactory receptor family 10 subfamily J member 5Genealiases: MOR23 · OLFR16 · OR1-28
Q-omics provides the consensus-scored OR10J5 profile across patient tissues and cancer cell-line models. OR10J5 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, OR10J5 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, OR10J5 RNA expression shows 6,997 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight CHOL, KIRC, and COAD as cancer lineages where OR10J5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR10J5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR10J5 survival associations across molecular data types. OR10J5 RNA expression shows survival associations in the most cancer types (12), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR10J5 RNA expression–survival associations across cancer types. High OR10J5 expression shows unfavorable associations in CHOL, UCS, MESO, PAAD, LUSC and SKCM. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for OR10J5 RNA expression.
This table summarizes OR10J5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OR10J5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR10J5 shows lower tumor expression in KIRC and CHOL. The KIRC box plot shows higher OR10J5 RNA expression in normal versus tumor tissue (log2 FC = −0.022, t-test p = .015).
This table shows molecular features associated with OR10J5 in patient tissues and cancer cell lines. In patient samples, OR10J5 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OR10J5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
